Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 07 Jun 2016 Interim results (retrospective analysis, n = 21) assessing NLR as a prognostic indicator presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results of interim analysis (n=21) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 03 Jan 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2018 as reported by ClinicalTrials.gov.